Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Autoantibodies against complete p53 protein and 18-mer peptides of p53 in ovarian cancer patients and healthy women were examined. Sera from 9% (4/46) of ovarian cancer patients but none (0/51) of healthy women recognized complete p53 protein. The antibodies were mainly of the IgG1 isotype. Two patients had also IgG2 antibodies. Sera from 28% (13/46) of cancer patients and 21% (11/52) of healthy women contained either IgM, or IgM plus IgG2 antibodies against 18-mer p53 peptides. Screening against complete p53 protein instead of peptides seems necessary for identifying patients with tumor-related antibodies. IgG2 antibodies against p53 suggest p53-specific CD4+ T helper 1 cell activity in some of the ovarian cancer patients.
Vennegoor
C J
CJ
Department of Obstetrics and Gynecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. c.vennegoor@azvu.nl
Nijman
H W
HW
Drijfhout
J W
JW
Vernie
L
L
Verstraeten
R A
RA
von Mensdorff-Pouilly
S
S
Hilgers
J
J
Verheijen
R H
RH
Kast
W M
WM
Melief
C J
CJ
Kenemans
P
P
D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D010455:Peptides / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010455:Peptides; D016159:Tumor Suppressor Protein p53